Connor, Clark & Lunn Investment Management Ltd. Chimerix Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Chimerix Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 344,712 shares of CMRX stock, worth $303,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares
344,712
Previous 206,614 66.84%
Holding current value
$303,346
Previous $181,000 76.8%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$0.77 - $1.07 $106,335 - $147,764
138,098 Added 66.84%
344,712 $320,000
Q2 2024

Aug 09, 2024
BUY
$0.87 - $1.05 $7,453 - $8,995
8,567 Added 4.33%
206,614 $181,000
Q1 2024

May 09, 2024
SELL
$0.91 - $1.26 $18,680 - $25,865
-20,528 Reduced 9.39%
198,047 $209,000
Q4 2023

Feb 09, 2024
SELL
$0.9 - $1.06 $45,096 - $53,113
-50,107 Reduced 18.65%
218,575 $209,000
Q3 2023

Nov 13, 2023
SELL
$0.94 - $1.23 $7,279 - $9,525
-7,744 Reduced 2.8%
268,682 $257,000
Q2 2023

Aug 10, 2023
BUY
$1.1 - $1.54 $60,925 - $85,295
55,387 Added 25.06%
276,426 $334,000
Q1 2023

May 09, 2023
SELL
$1.19 - $2.09 $49,224 - $86,452
-41,365 Reduced 15.76%
221,039 $278,000
Q4 2022

Feb 10, 2023
BUY
$1.67 - $2.35 $367,762 - $517,509
220,217 Added 522.0%
262,404 $488,000
Q3 2022

Nov 10, 2022
SELL
$1.81 - $2.76 $227,498 - $346,904
-125,690 Reduced 74.87%
42,187 $81,000
Q2 2022

Aug 05, 2022
SELL
$1.34 - $5.34 $79,846 - $318,194
-59,587 Reduced 26.2%
167,877 $349,000
Q1 2022

May 12, 2022
SELL
$4.58 - $6.8 $512,181 - $760,444
-111,830 Reduced 32.96%
227,464 $1.04 Million
Q4 2021

Feb 10, 2022
SELL
$5.23 - $7.18 $17,164 - $23,564
-3,282 Reduced 0.96%
339,294 $2.18 Million
Q3 2021

Nov 12, 2021
BUY
$5.94 - $8.75 $865,012 - $1.27 Million
145,625 Added 73.94%
342,576 $2.12 Million
Q2 2021

Aug 12, 2021
SELL
$7.54 - $9.79 $81,266 - $105,516
-10,778 Reduced 5.19%
196,951 $1.58 Million
Q1 2021

May 13, 2021
SELL
$4.76 - $11.25 $572,499 - $1.35 Million
-120,273 Reduced 36.67%
207,729 $2 Million
Q4 2020

Feb 16, 2021
SELL
$2.43 - $5.42 $67,867 - $151,375
-27,929 Reduced 7.85%
328,002 $1.58 Million
Q3 2020

Nov 12, 2020
SELL
$2.3 - $3.72 $150,613 - $243,600
-65,484 Reduced 15.54%
355,931 $886,000
Q2 2020

Aug 13, 2020
SELL
$1.33 - $3.63 $38,008 - $103,738
-28,578 Reduced 6.35%
421,415 $1.31 Million
Q1 2020

May 13, 2020
SELL
$1.27 - $2.33 $31,369 - $57,551
-24,700 Reduced 5.2%
449,993 $647,000
Q4 2019

Feb 12, 2020
SELL
$1.3 - $2.72 $780 - $1,632
-600 Reduced 0.13%
474,693 $964,000
Q3 2019

Nov 13, 2019
BUY
$1.93 - $4.21 $60,891 - $132,825
31,550 Added 7.11%
475,293 $1.12 Million
Q2 2019

Aug 07, 2019
BUY
$2.05 - $4.32 $143,227 - $301,825
69,867 Added 18.69%
443,743 $1.92 Million
Q1 2019

May 08, 2019
BUY
$1.79 - $3.12 $126,160 - $219,900
70,481 Added 23.23%
373,876 $785,000
Q4 2018

Feb 12, 2019
BUY
$2.24 - $3.9 $24,752 - $43,095
11,050 Added 3.78%
303,395 $780,000
Q3 2018

Nov 13, 2018
BUY
$3.58 - $4.9 $55,321 - $75,719
15,453 Added 5.58%
292,345 $1.14 Million
Q2 2018

Aug 02, 2018
BUY
$4.43 - $5.14 $5,134 - $5,957
1,159 Added 0.42%
276,892 $1.32 Million
Q1 2018

May 14, 2018
BUY
$4.65 - $5.9 $70,563 - $89,532
15,175 Added 5.82%
275,733 $1.43 Million
Q4 2017

Feb 09, 2018
SELL
$4.32 - $5.52 $29,859 - $38,154
-6,912 Reduced 2.58%
260,558 $1.21 Million
Q3 2017

Nov 14, 2017
BUY
$4.35 - $5.25 $145,812 - $175,980
33,520 Added 14.33%
267,470 $1.4 Million
Q2 2017

Aug 14, 2017
BUY
N/A
233,950
233,950 $1.28 Million

Others Institutions Holding CMRX

# of Institutions
71
Shares Held
37M
Call Options Held
52.7K
Put Options Held
130K
View Full List

About CHIMERIX INC

CMRX Quotes by TradingView
  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $77.1M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email